Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.

Heslop CL, Frohlich JJ, Hill JS.

J Am Coll Cardiol. 2010 Mar 16;55(11):1102-9. doi: 10.1016/j.jacc.2009.11.050.

2.

Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.

Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA.

Coron Artery Dis. 2010 May;21(3):129-36. doi: 10.1097/MCA.0b013e328333f50d.

PMID:
20305551
3.

Serial analyses of C-reactive protein and myeloperoxidase in acute coronary syndrome.

Borges FK, Borges FK, Stella SF, Souza JF, Wendland AE, Werres Junior LC, Ribeiro JP, Polanczyk CA.

Clin Cardiol. 2009 Nov;32(11):E58-62. doi: 10.1002/clc.20462.

4.

High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease.

Jánoskuti L, Förhécz Z, Hosszúfalusi N, Kleiber M, Walentin S, Bálint O, Duba J, Rugonfalvi-Kiss S, Romics L, Karádi I, Füst G, Prohászka Z.

Eur J Clin Invest. 2005 Feb;35(2):104-11.

PMID:
15667581
5.

Prognostic value of plasma myeloperoxidase in ESRD patients.

Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE.

Am J Kidney Dis. 2010 Nov;56(5):937-46. doi: 10.1053/j.ajkd.2010.05.008. Epub 2010 Jul 16.

PMID:
20638167
6.

Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.

Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ.

Circulation. 2002 Mar 26;105(12):1412-5.

7.

Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure.

Michowitz Y, Kisil S, Guzner-Gur H, Rubinstein A, Wexler D, Sheps D, Keren G, George J.

Isr Med Assoc J. 2008 Dec;10(12):884-8.

8.

Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.

Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, Schömig A, Kastrati A.

Am Heart J. 2008 Feb;155(2):356-60. doi: 10.1016/j.ahj.2007.10.017. Epub 2007 Dec 19.

PMID:
18215608
9.

High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease.

Speidl WS, Graf S, Hornykewycz S, Nikfardjam M, Niessner A, Zorn G, Wojta J, Huber K.

Am Heart J. 2002 Sep;144(3):449-55.

PMID:
12228781
10.

Inflammatory biomarkers in coronary artery disease.

Zakynthinos E, Pappa N.

J Cardiol. 2009 Jun;53(3):317-33. doi: 10.1016/j.jjcc.2008.12.007. Epub 2009 Jan 29. Review.

11.

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J; PEACE Investigators.

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2463-9. Epub 2007 Aug 31.

12.
13.

Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease.

Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL; Intermountain Heart Collaborative (IHC) Study Group.

Circulation. 2003 Jan 21;107(2):258-63.

14.

Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction.

Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB; Intermountain Heart Collaborative (IHC) Study Group.

Am J Cardiol. 2002 Jan 15;89(2):145-9.

PMID:
11792332
15.

Increased advanced oxidation protein products in Behçet's disease: a new activity marker?

Yazici C, Köse K, Caliş M, DemIr M, Kirnap M, Ateş F.

Br J Dermatol. 2004 Jul;151(1):105-11.

PMID:
15270878
16.
17.

Combined polymorphisms in oxidative stress genes predict coronary artery disease and oxidative stress in coronary angiography patients.

Heslop CL, Tebbutt SJ, Podder M, Ruan J, Hill JS.

Ann Hum Genet. 2012 Nov;76(6):435-47. doi: 10.1111/j.1469-1809.2012.00731.x. Epub 2012 Sep 25.

18.

Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure.

Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL.

Congest Heart Fail. 2011 May-Jun;17(3):105-9. doi: 10.1111/j.1751-7133.2011.00221.x. Epub 2011 Mar 31.

19.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators.

Circulation. 2007 Mar 27;115(12):1528-36. Epub 2007 Mar 19.

20.

Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting.

van der Harst P, Voors AA, Volbeda M, Buikema H, van Veldhuisen DJ, van Gilst WH.

Am J Cardiol. 2006 Jun 15;97(12):1697-701. Epub 2006 Apr 21.

PMID:
16765116

Supplemental Content

Support Center